Efficacy of butyric acid preparations in patients with hepatocellular carcinoma undergoing chemotherapy

Efficacy of butyric Acid preparations in patients with unresectable hepatocellular carcinoma underGoing systEmic chemotheRapy - EAGER study

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs061230077

Enrollment

Registered

2023-11-15

Start date

2024-04-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unresectable hepatocellular carcinoma Unresectable HCC

Interventions

Patients with unresectable hepatocellular carcinoma will receive MiyaBM granule orally at a dose of 1.5g or MiyaBM 3 tablets per day. This will be administered until progress of tumor(assume average

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 18 age old over 2 Regardless of gender 3 Patients diagnosed with unresectable hepatocellular carcinoma 4 Patients who will receive treatment with Durvalumab and Tremelimumab 5 Patients who have been fully informed consent

Exclusion criteria

Exclusion criteria: 1 Patients with Child-Pugh score over 8 2 Patients used to have hypersensitivity with butyric acid 3 Being pregnant or possibly pregnant 4 Patients who judged as inappropriate candidate by the chief medical examine

Design outcomes

Primary

Measure	Time frame
progression free survival	—

Secondary

Measure	Time frame
1 Response rate 2 Disease cotrol rate 3 Overall survival 4 Change of intestinal flora 5 Adverse Events and side effects	—

Contacts

Public ContactMasahiko Sue

Okayama University Hospital

p58q0soo@okayama-u.ac.jp+81-86-235-7219

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026